These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 15693143)
1. Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms. Funk J; Schmitz G; Failing K; Burkhardt E Cancer Immunol Immunother; 2005 Jan; 54(1):87-92. PubMed ID: 15693143 [TBL] [Abstract][Full Text] [Related]
2. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro. Helfand SC; Soergel SA; Modiano JF; Hank JA; Sondel PM Cancer Biother; 1994; 9(3):237-44. PubMed ID: 7820185 [TBL] [Abstract][Full Text] [Related]
3. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs. Da Pozzo LF; Hough KL; Holder WD Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858 [TBL] [Abstract][Full Text] [Related]
4. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes. Flexman JP; Manning LS; Robinson BW Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789 [TBL] [Abstract][Full Text] [Related]
5. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity. Brooks B; Rees RC Clin Exp Immunol; 1988 Nov; 74(2):162-5. PubMed ID: 3265652 [TBL] [Abstract][Full Text] [Related]
6. Intracellular calcium changes associated with in vitro lymphokine-activated killer and natural killer cell cytotoxicity. Burkey BB; Omann GM; Wolf GT Arch Otolaryngol Head Neck Surg; 1991 Nov; 117(11):1281-6. PubMed ID: 1747234 [TBL] [Abstract][Full Text] [Related]
7. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma. Muralikrishna K; Varalakshmi C; Khar A Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244 [TBL] [Abstract][Full Text] [Related]
8. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes. Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597 [TBL] [Abstract][Full Text] [Related]
9. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2. McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959 [TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors. Mitchell DH; Withrow SJ; Johnston MR; Kruse CA Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269 [TBL] [Abstract][Full Text] [Related]
11. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179 [TBL] [Abstract][Full Text] [Related]
13. Isolation of human NK cells and generation of LAK activity. Whiteside TL Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847 [TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells. Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622 [TBL] [Abstract][Full Text] [Related]
15. Characterization of effector-target conjugates for cloned human natural killer and human lymphokine activated killer cells by flow cytometry. Callewaert DM; Radcliff G; Waite R; LeFevre J; Poulik MD Cytometry; 1991; 12(7):666-76. PubMed ID: 1782834 [TBL] [Abstract][Full Text] [Related]
16. Age related natural killer activity of peripheral blood lymphocytes from healthy subjects and cancer patients. A comparative in vitro study with interleukin-2. Chakraborty A; Chakraborty NG; Chattopadhyay U Tumori; 1994 Jun; 80(3):233-7. PubMed ID: 8053083 [TBL] [Abstract][Full Text] [Related]
17. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity. Furbert-Harris PM; Evans CH Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871 [TBL] [Abstract][Full Text] [Related]
18. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells. Zhai YF; Esselman WJ; Oakley CS; Chang CC; Welsch CW Cancer Immunol Immunother; 1992; 35(4):237-45. PubMed ID: 1511458 [TBL] [Abstract][Full Text] [Related]
19. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition. Mueller EA; Anderer FA Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765 [TBL] [Abstract][Full Text] [Related]
20. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients. Sone S; Kunishige E; Fawzy F; Yanagawa H; Nii A; Maeda K; Atagi S; Heike Y; Nishioka Y; Mizuno K Jpn J Cancer Res; 1991 Jun; 82(6):716-23. PubMed ID: 1649813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]